Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy
A legfontosabb adatok
- Ki végzi
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Hol
- Beijing, Hangzhou, Huzhou, Jiaxing, Nanning, Ningbo és Taizhou (Kína)Mind a 7 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2/3. fázis
- Résztvevők
- 150 fő, tervezett
- Kezdés
- 2026. aug. 27.
- Várható befejezés
- 2027. okt. 10.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- 3-N-butylphthalide
- A regiszteradat frissítve
- 2026. október 16.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with multiple system atrophy (MSA), a disease that damages the nervous system. It tests NBP capsules against a placebo (dummy capsule) for 6 months.
- Életkor
- 30 to 80 years
- Nem
- All sexes
- A betegség stádiuma
- "Clinically established MSA" by the 2022 MDS criteria, confirmed by a neurologist. Diagnosis within the last 5 years. Life expectancy over 3 years. Not fully wheelchair-bound or bedridden. Able to do tests, including MRI and PET-CT scans.
- Korábbi kezelés
- Must have been on stable medicines for at least one month before the trial. These may include drugs for Parkinson symptoms, autonomic problems, anxiety or depression, and sleep.
A részvétel fő kizáró okai
- Diagnosis changed to another disease, such as Parkinson's disease or progressive supranuclear palsy
- Other major brain disease, such as stroke, brain bleeding, epilepsy or encephalitis, or psychiatric disorders with psychotic symptoms
- Severe liver or kidney problems (ALT or AST >2 xULN; creatinine clearance <30 mL/min), bleeding in the past 3 months or high bleeding risk
- Severe memory and thinking problems (MMSE score <24), cancer or autoimmune disease, or trouble swallowing
- Pregnant, breastfeeding, or planning a pregnancy within the next year
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Meet a diagnosis for "clinically established MSA" according to the Movement Disorder Society (MDS) diagnostic criteria for multiple system atrophy revised in 2022, as assessed by a neurologist
- Patients aged between 30 and 80 years, within 5 years since the initial diagnosis of MSA, and with a life expectancy greater than 3 years
- Patients are not entirely dependent on a wheelchair or bedridden and are capable of cooperating with necessary assessments and examinations, including scale evaluations, magnetic resonance imaging (MRI), and PET-CT scans
- Patients must have been on a stable medication regimen (for a duration of at least one month) prior to the trial, which may include drugs for anti-Parkinson, anti-autonomic dysfunction, anti-anxiety/depression agents, and sleep aids
Ki nem vehet részt
- Patients with a diagnosis confirmed by PET-CT or revised during follow-up to other diseases, such as idiopathic Parkinson's disease, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, or secondary parkinsonian syndromes
- Patients with a history of other major neurological disorders, including ischemic stroke, intracranial hemorrhage, epilepsy, encephalitis, or central nervous system demyelinating diseases
- Patients with a history of psychiatric disorders that may involve psychotic symptoms, such as schizophrenia, major depressive disorder, or dissociative -conversion disorders
- Patients with a heamorrhage event within the past 3 months or a high bleeding risk
- Patients with a history of significant craniocerebral trauma or surgery
- Patients with severe cognitive impairment (Mini-Mental State Examination [MMSE] score <24)
- Patients with a history of malignancy or autoimmune diseases
- Patients with dysphagia due to severe medullary dysfunction or esophageal disorders, or those unable to comply with medication administration for other reasons
- Patients with severe hepatic or renal impairment (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] levels >2 xULN; Estimated creatinine clearance <30 mL/min
- Patients who are pregnant, lactating, or planning a pregnancy within the next year
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 30 és 80 év között vagy?
Helyszínek itt: Kína
- Affiliated Beijing Chaoyang Hospital of Capital Medical UniversityBeijing, KínaContact: Chaodong Wang, MDToborzás még nem indult
- The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, KínaContact: Jiali Pu, MDRésztvevőt keres
- Huzhou Central HospitalHuzhou, KínaContact: Ying Tan, MDRésztvevőt keres
- The Second Hospital of JiaxingJiaxing, KínaContact: Yanping Wang, MDRésztvevőt keres
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, KínaContact: Yousheng Xiao, MDToborzás még nem indult
- Ningbo Second HospitalNingbo, KínaContact: Weinv Fan, MDRésztvevőt keres
- Taizhou Hospital of Zhejiang ProvinceTaizhou, KínaContact: Suzhi Liu, MDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The present study aims to conduct a randomized controlled trial to evaluate the efficacy and safety of 3-n-Butylphthalide (NBP) in improving symptoms in patients with Multiple System Atrophy (MSA). The main questions it aims to answer are:
A teljes eredeti leírásKevesebb
1. To evaluate whether NBP soft capsules, compared with placebo, alleviates the major clinical symptoms in patients with MSA. 2. Whether NBP application is safe to treat patients with MSA. In this trial, NBP will be compared with placebo (similar soft capsule without effective component of NBP) to demonstrate if NBP can alleviates MSA symptoms
Participants of ENMSA will:
1. Take NBP or Placebo three times a day for 6 months 2. Be served with clinical visit four times for follow-up and tests 3. Keep a diary of drug application and symptom changes
A vizsgálat 2 csoportja
- NBP treatment groupA vizsgált kezelés
Participants in the NBP treatment group will receive NBP soft capsules (dosage form: 100 mg/capsule), two capsules per dose, three times daily (total daily dose of 600 mg). The whole treatment duration is six months, during which all patients will maintain their original medication unchanged.
Kezelés: 3-N-butylphthalide
- Placebo control groupPlacebo, összehasonlításként
Participants in the Placebo control group will receive two Placebo soft capsules each time, three times daily (total daily dose of 600 mg). The whole application duration is six months, during which all patients will maintain their original medication unchanged.
Kezelés: 3-N-butylphthalide
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy(ENMSA): A Multicenter, Randomised, Double-blinded, Placebo-controlled Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07518810: ki vehet részt
- A regiszteradat frissítve
- 2026. október 16.